Literature DB >> 11357169

Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods.

H K Genant1.   

Abstract

OBJECTIVE: The Genant/Sharp scoring method is a validated radiologic scoring system useful for diagnosing, classifying, and defining specific clinical problems associated with rheumatoid arthritis (RA). The Genant/Sharp scoring method is described, and its level of correlation with the Larsen scoring method is discussed.
METHOD: The Genant/Sharp scoring system evaluates erosion, joint space narrowing (JSN), and a combination of erosion and JSN referred to as the total score. This method was used to determine change in radiographic progression during 2 consecutive 6-month intervals within a multicenter, double-blind, placebo-controlled study of recombinant human interleukin-1 receptor antagonist (IL-1ra) in patients with RA. These results were compared with the results obtained through the Larsen scoring method to determine their correlation.
RESULTS: The Genant/Sharp scoring method showed a moderate correlation with the Larsen scoring method, particularly at baseline, and showed similar treatment trends in a study of IL-1ra in patients with RA.
CONCLUSION: The Genant/Sharp scoring method provides an alternative to the Sharp and Larsen approaches for radiographic assessment in RA. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11357169     DOI: 10.1053/sarh.2001.23697

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  6 in total

Review 1.  Interpreting radiographic data in rheumatoid arthritis.

Authors:  P A Ory
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

Review 2.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

3.  Abatacept for the treatment of rheumatoid arthritis: A review.

Authors:  Jeffrey L Kaine
Journal:  Curr Ther Res Clin Exp       Date:  2007-11

4.  Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data.

Authors:  Maasa Hama; Takeaki Uehara; Kaoru Takase; Atsushi Ihata; Atsuhisa Ueda; Mitsuhiro Takeno; Kazuya Shizukuishi; Ukihide Tateishi; Yoshiaki Ishigatsubo
Journal:  Rheumatol Int       Date:  2011-02-04       Impact factor: 2.631

5.  Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial.

Authors:  H K Genant; C G Peterfy; R Westhovens; J-C Becker; R Aranda; G Vratsanos; J Teng; J M Kremer
Journal:  Ann Rheum Dis       Date:  2007-12-17       Impact factor: 19.103

6.  Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.

Authors:  G Wells; J-C Becker; J Teng; M Dougados; M Schiff; J Smolen; D Aletaha; P L C M van Riel
Journal:  Ann Rheum Dis       Date:  2008-05-19       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.